In the competitive field of Heterocyclic Biocides, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Heterocyclic Biocides technology and learn how to protect your intellectual property.

Patent challenges are becoming increasingly common in the Heterocyclic Biocides industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Heterocyclic Biocides industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Heterocyclic Biocides industry

EP3007695Compositions And Methods For Treating AnemiaAKEBIA THERAPEUTICS INC.Nov 6, 2024SANDOZ AG
EP3707128Injectable Isoxazoline Pharmaceutical Compositions And Their Use Against Parasite InfestationINTERVET INTERNATIONAL B.V.Sep 16, 2024VIRBAC
EP3522714Pesticidal MixturesBASF SEMay 30, 2024SYNGENTA CROP PROTECTION AG
EP3599857Herbicidal MixturesBAYER AKTIENGESELLSCHAFTMay 22, 2024BASF SE
EP3189105Products Preserved With 5-Chloro-2-Methyl-4-Isothiazolin-3-OneTHOR GMBHMar 20, 2024ARXADA AG
EP3733672Heterocyclic Compounds And Noxious Arthropod Control Agent Containing SameSUMITOMO CHEMICAL COMPANY, LIMITEDDec 20, 2023BOEHRINGER INGELHEIM VETMEDICA GMBH
EP3663282Pyrrolidinone HerbicidesFMC CORPORATIONFeb 18, 2023SYNGENTA CROP PROTECTION AG
EP3427584A Method For Controlling RustUPL LTDJan 2, 2023SYNGENTA CROP PROTECTION AG
EP2658541Topical Localized Isoxazoline Formulation Comprising GlycofurolINTERVET INTERNATIONAL B.V.Oct 25, 2022VIRBAC
EP3300601Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative DisordersROTALEC IP HOLDINGS LLCOct 12, 2022GENERICS UK

To stay ahead in the competitive Heterocyclic Biocides industry, companies are constantly innovating. Here are the top patents facing oppositions in the Heterocyclic Biocides industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2350096Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS, LTD.8
EP2203053Sep 20, 2017Modified Starch Material Of Biocompatible HemostasisJI, XIN3
EP3300601Jan 12, 2022Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative DisordersCELATOR PHARMACEUTICALS, INC.3
EP2252148Mar 20, 2019Methods For Treating Bowel DiseasesSALIX PHARMACEUTICALS, LTD.3
EP2081550May 26, 2021Coating Capsules With Active Pharmaceutical IngredientsRELIANT PHARMACEUTICALS, INC.2
EP2120568Nov 15, 2017Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative DisordersCELATOR PHARMACEUTICALS, INC.2
EP2488033Jun 12, 2019CombinationGLAXOSMITHKLINE LLC2
EP2545777Jan 18, 2023Isoxazoline Compositions And Their Use As AntiparasiticsINTERVET INTERNATIONAL B.V.2
EP2306837Oct 25, 2023Pestcidal Active Mixtures Comprising Isoxazoline Compounds IBASF SE2
EP2563115Nov 8, 2017Stabilized Agricultural Oil DispersionsDOW AGROSCIENCES, LLC2